Abstract. In a single-center double-blind, randomized trial in West Africa, we evaluated the safety and immunogenicity of a new pasteurized, pepsin-digested equine tetanus immunoglobulin (heat-treated equine tetanus immunoglobulin [HT-ETIG]) in the post-exposure prophylaxis of tetanus compared with the reference product, equine tetanus immunoglobulin (ETIG). A total of 134 adults presenting to Garoua Hospital, Cameroon with a tetanus-prone wound were randomized to receive a 3,000 international units (IU) intramuscular injection (deltoid) of either HT-ETIG or ETIG, simultaneously with a tetanus-diphtheria vaccine. No serious adverse reactions were reported. The incidences of local and systemic reactions were similar in the two groups. Repeated measures of equine tetanusantibody levels measured from Day 0 to Day 28 showed that titers were significantly higher in the HT-ETIG group (P ϭ 0.017). At Day 7, a higher percentage of subjects in the HT-ETIG group had equine antibody levels Ն 0.1 IU/ ml (80.4% versus 37.9%; P Ͻ 0.0001). No cases of tetanus occurred during the follow-up, attesting to the efficacy of the combined prophylactic treatment.
INTRODUCTION
Tetanus is still a major public health problem in most developing countries. In 1995, according to the World Health Organization (WHO) at least 450,000 deaths were attributable to neonatal tetanus. 1 Non-neonatal tetanus accounts for 500,000 cases, with a death rate of about 40%. 2 In developing countries, unlike diphtheria for which there is some natural immunological boosting, anti-tetanus immunity in adults is low. 3, 4 Due to extensive coverage with tetanus-toxoid vaccine, morbidity and mortality due to this disease have decreased dramatically but not disappeared in developed countries, especially in the elderly. [5] [6] [7] [8] Despite medical control of convulsions and the provision of assisted ventilation, the case fatality rate of tetanus is still high (range, 7-58%), even in countries with high medical standards. 5, 7 Prophylaxis of tetanus consists of local wound management, passive immunization (tetanus-specific immunoglobulin), and active immunization (vaccine). The use of passive anti-tetanus immunotherapy aims to neutralize circulating toxin before it reaches the nervous system. To overcome the limitations (anaphylaxis, late serum sickness), related to the first ''crude'' equine anti-tetanus serum, human homologous anti-tetanus immunoglobulins were developed that were virtually free of reactions, but, due to their cost, are neither readily available nor affordable in most developing countries. 9 Consequently, peptic hydrolysis of equine immunoglobulin was used to obtain F(abЈ) 2 fragments which bear toxin neutralizing activity. Purification techniques of thermocoagulation and ammonium sulfate precipitation were developed to reduce the risk of reactions to non-Ig proteins associated with the use of equine anti-tetanus serum.
For over 20 years, Pasteur Mérieux Connaught (PMC) has manufactured a purified equine anti-tetanus immunoglobulin (ETIG) that contains pepsin-digested IgG (85% as F(abЈ) 2 ). These split immunoglobulins are available in developing countries and thus represent a valuable alternative to the human product. 10 Use of equine anti-tetanus F(ab') 2 is indicated in the treatment of persons with recent injuries that might be contaminated with tetanus spores who have not received vaccination in the previous 10 years or whose prior vaccination schedule is incomplete or unknown. To further reduce an already very low risk of virus passage via immune globulin administration, a pasteurization step has been added to the manufacturing process. This new ETIG (HT-ETIG) is heated for 10 hours at 58-60ЊC. In addition, metacresol, a phenolic preservative normally present in the ETIG, is not used during the manufacture of HT-ETIG.
The purpose of the present study was to test under field conditions of tetanus exposure this new HT-ETIG in terms of antibody levels and rates of local and systemic reactions in comparison with the current reference product (ETIG). Immunoglobulin was administered as part of a post-exposure prophylactic treatment for suspected tetanus exposure in a tropical country setting. To evaluate the protective effect of F(abЈ) 2 fragments, a specific titration method was developed to differentiate them from human antibodies elicited by tetanus-diphtheria (Td) vaccine.
MATERIALS AND METHODS

Study population.
Between 1995 and 1996, 134 African subjects were enrolled in the Garoua Hospital in Cameroon. All subjects presented a cutaneous tetanus-prone wound and required post-exposure treatment. Written informed consent was obtained from all subjects, after they were informed of the nature of the trial and its potential risks. The consent form was written in French, but nurses or investigators translated and explained this document to the patient in the local language when necessary. The trial was conducted in accordance with the latest revision of the Declaration of Helsinki, Good Clinical Practice, and local regulatory requirements. The protocol had been approved by the National Ethics Committee of the Health Ministry of Cameroon.
Inclusion criteria were adults (Ͼ 15 years old) of either sex who presented with either a clean-major or tetanus-prone wound defined as category II, or a tetanus-prone wound with delayed or incomplete debridement, defined as category III. As vaccination cards or records of previous tetanus vaccination were rarely available in our rural African population, we based our recruitment on subjects who denied any previous vaccination against tetanus in the previous 10 years.
Exclusion criteria were history of an adverse reaction to equine immunoglobulins or allergy to any component of the Td vaccine, pregnancy, and known immunosuppressive disease or treatment with immunosuppressive therapy (including corticosteroids) within the previous month.
Study design. This was a single center double-blind, randomized trial. During the first visit, after wound care and checking the inclusion and exclusion criteria, the investigator assigned a randomization number to each subject in chronological order of recruitment. The number corresponded to treatment with either HT-ETIG ϩ Td vaccine or ETIG ϩ Td vaccine.
Groups were balanced such that 67 subjects received ETIG (3,000 IU) and Td vaccine, and 67 received HT-ETIG (3,000 IU) and Td vaccine. A dose of 1,500 units is recommended for the treatment of clean-major wounds or tetanus-prone wounds in association with tetanus vaccine but the dose is doubled (3,000 units) in the event of delayed or incomplete debridement of a tetanus-prone wound or in the case of burns, bleeding or infected wounds, or if the subject is an adult of above average weight. 11 A pre-treatment blood sample for tetanus antibody titration (equine and human) and anti-diphtheria antibody titration was obtained. Patients were followed for 30 minutes after treatment to detect immediate reactions. The subjects were then given a self-monitoring form and asked to record local or systemic symptoms for 28 days.
Subjects returned for follow-up visits on Days 1, 3, 5, 7, 11, 14, 21, and 28, during which safety was evaluated and blood samples were obtained. Diphtheria antibody titration was performed on samples obtained on Days 0 and 28.
ETIG and Td vaccine administration. Equine tetanus immunoglobulin and Td vaccine were manufactured by Pasteur Merieux Connaught, Lyon, France. For the two equine tetanus immunoglobulin products, the immunization procedures of horses, plasma collection, and overall manufacturing processes (except those specific to HT-ETIG, see above) were similar.
HT-ETIG was composed of tetanus F(abЈ) 2 fragments Ն 1,500 IU/mL (mouse potency test), Tween 80 (50 mg/L), and sodium chloride, 0.9% (w/v); and water for injection (up to 1 mL). The product was presented in a glass ampoule containing 1.0 mL. Three batches were used in this study (S3086, S3089, S3102) with the aim of assessing the consistency of production. Their protein content and activity were 2.2-2.7 g/100 mL and 1,800-1,950 IU/mL, respectively.
ETIG was composed of tetanus F(abЈ) 2 fragments Ն 1,500 IU/mL (mouse potency test), glycine (10 g/L), sodium chloride, 0.5% (w/v), metacresol Յ 1.5 g/L, and water for injection (up to 1 mL). The product was presented in a 1.0 mL glass ampoule. The usual commercial batch used in this study was L5463, with a protein content and activity of 2.1 g/100 mL and 1,800 IU/mL, respectively.
Td-adsorbed vaccine was composed of purified diphtheria toxoid not less than 2 IU (the lower limit of the 95% confidence interval of potency measured according to the assay described in the European Pharmacopoeia with reference to the WHO international standard) per single human dose and purified tetanus toxoid not less than 20 IU (the lower limit of the 95% confidence interval of potency as above) per single dose; aluminum hydroxide to a maximum of 1.25 mg, sodium mercurothiolate, and water for injection (up to 0.5 mL). The product was presented in a glass, needle-sealed 0.5 mL syringe. The usual commercial batch used in this study was S2909.
Route of administration. Two mL of either HT-ETIG or ETIG (3,000 IU) (the contents of two ampoules of 1500 IU/ mL each) was injected slowly into the right deltoid. A single 0.5 mL dose of Td vaccine was injected into the left deltoid by the intramuscular route. Based on previous experience with purified equine rabies immunoglobulin, we did not use a skin test before administration of ETIG because of the low sensitivity and specificity of this test and also because in practical terms human tetanus immunoglobulin was not available as an alternative treatment at this center. 12 Measures such as epinephine and emergency material to control anaphylactic reactions were readily available.
Determination of tetanus-antibody levels. Plasma levels of equine anti-tetanus fragments F(abЈ) 2 were determined on Days 0, 1, 3, 7, 11, 14, 21, and 28 from a 5 mL blood sample taken at each time. Equine anti-tetanus F(abЈ) 2 fragments in human serum were assayed by a specific solid-phase enzyme-linked immunosorbent assay (ELISA) developed by the PMC Seroimmunology Laboratory (C. Blondeau). This assay was carried out on microtitration plates coated with purified tetanus toxoid. A peroxidase-conjugated goat antihorse IgG F(abЈ) 2 fragment-specific antibody was used. Results were expressed in IU per mL. The sensitivity of the assay (lower limit of quantitation in serum) was 0.005 IU/ ml.
Human anti-tetanus and anti-diphtheria IgG antibodies were assayed by a validated enzyme-linked immunosorbent assay (ELISA) procedure. 13 Results were expressed in IU per mL. Human anti-tetanus IgG antibodies were assayed at the same time as equine F(abЈ) 2 . Anti-diphtheria antibodies were assayed before and 28 days after immunization.
Subjects with a tetanus-antibody titer Ͻ 0.01 IU/mL were considered unprotected. Those with a titer in the range of 0.01 and up to but not including 0.1 IU/mL were considered to have possible, but uncertain, protection. Those with a titer Ն 0.1 IU/mL were considered to have definite seroprotection. 14 Safety analysis. All local reactions and systemic events occurring within 28 days after injection were recorded. During the study, safety information (local and systemic events) was noted by each subject on a self-monitoring form and then collected by the investigator at each visit. The local and systemic adverse events were classified by severity, time of onset, duration, and relation to the vaccine. For severity, adverse events were classified as mild, moderate, or severe according to a published rating scale. Fever intensity was ranked as mild if the rectal temperature was Ͻ 38.5ЊC, moderate if 38.5-40ЊC, or severe if Ͼ 40ЊC. The duration of reactions was classified according to Ͻ 24 hours, 24-72 hours, and Ն 72 hours.
Safety results were expressed as the number and percentage of subjects in each group with one or more local reactions at the injection site, i.e., pain, redness, pruritus, swelling/induration, and the number and percentage of subjects presenting one or more systemic reactions, i.e., fever, edema, urticaria, rash, malaise, arthralgia/myalgia, headache, or gas- trointestinal disorders such as nausea, vomiting, diarrhea, or abdominal pain following treatment. Statistical analysis. It was planned to include 40 subjects in each group with the aim of having 90% power to detect adverse events with an incidence of Ն 5%. A total 67 subjects in each group were enrolled to take into account dropouts and subjects with protocol deviations.
Geometric mean antibody titers (GMT) were calculated by day post-injection from individual measurements of serum levels for each group. Descriptive data on serum levels of equine tetanus F(abЈ) 2 fragments were given in each group, and the profiles were plotted from eight data points (Day 0 to Day 28). Groups were compared for categorical data (sex ratio, characteristics of wound, incidence of adverse reactions, and rate of seroprotection) using the chisquare test, or the Fisher's exact test for small sample sizes, and for continuous data (age) using either the Student's ttest or Wilcoxon's test depending on whether or not group data followed a normal distribution. In addition, changes in anti-tetanus antibodies after equine tetanus immunoglobulin administration were compared between the two groups using a repeated measures F analysis of variance (ANOVA). A P value Յ 0.05 was considered to indicate significance. All data were analysed with SAS software version 6.06 (SAS Inc., Cary, NC).
RESULTS
Group characteristics.
A total of 134 subjects (67 per group) were included in this study. Twenty-four subjects left the study prematurely, and of these, only five were lost to follow-up. Age, height, weight, and female/male ratio (summarized in Table 1 ) did not differ between groups. The wound characteristics in the two groups are presented in Table 2. The category, number of wounds per subject, and wound localization were similar between groups. Among the 134 patients, 92 (68.7%) had a wound of category II and 42 (31.3%) had a wound of category III. Most wounds involved the head/neck, hand, and foot. The time between the wound and study inclusion could be determined for 120 patients and was 1.75 Ϯ 3.27 days (mean Ϯ SD) (range, 0-14 days) in the ETIG group, and 1.30 Ϯ 2.61 days (range, 0-13 days) in the HT-ETIG group.
Equine anti-tetanus F(ab) 2 fragments. Titers of equine anti-tetanus F(abЈ) 2 fragments up to 28 days post-injection are presented in Figure 1 . At Day 3, the GMT was 0.163 IU/mL (95% CI, 0.149-0.179 IU/mL) in the ETIG group and 0.221 IU/mL (95% CI, 0.207-0.237 IU/mL) in the HT-ETIG group. From Day 3 to Day 28, antibody titers decreased steadily in both groups. Repeated measures of AN-OVA on subjects for whom we had all antibody values from Day 1 to Day 28 (n ϭ 93) showed that the titers were significantly higher (P ϭ 0.017) in the HT-ETIG group. This difference is also apparent in Table 3 , which shows the seroprotection rates in the two groups according to different threshold levels (0.01, 0.05, 0.1 IU/mL). At Day 7, the percentage of subjects with a titer of equine anti-tetanus F(abЈ) 2 Ն 0.10 IU/mL was higher in the HT-ETIG (80.4%) than in ETIG group (37.9%) (P Ͻ 0.0001). All subjects had the FIGURE 1. Geometric mean titers (GMT) of equine antitetanic fragments F(abЈ) 2 (mean and 95% CI, log-linear scale) after administration of equine tetanus immunoglobulin (ETIG) ϩ tetanus-diphtheria (Td) vaccine or heat-treated equine tetanus immunoglobulin (HT-ETIG) ϩ Td vaccine. Repeated measures analysis of variance from Day 1 to Day 28 (n ϭ 93), showed that the titers were significantly higher (P ϭ 0.017) in the HT-ETIG group than in the ETIG group.
FIGURE 2. Geometric mean titers (GMT) of human antitetanic antibodies (mean and 95% confidence intervals [CI]
, log-linear scale) after administration of equine tetanus immunoglobulin (ETIG) ϩ tetanus-diphtheria (Td) vaccine or heat-treated equine tetanus immunoglobulin (HT-ETIG) ϩ Td vaccine. Human anti-tetanus and anti-diphtheria antibodies. Five days after vaccination, human anti-tetanus antibodies in response to vaccination increased moderately but similarly in both groups (Figure 2 ). In the ETIG group, human antitetanus antibodies increased from 0.022 IU/ml (95% CI, 0.013-0.035 IU/mL) before vaccination to 0.279 IU/ml (95% CI, 0.13-0.6 IU/mL) 28 days post-vaccination. In the HT-ETIG group, antibodies increased from 0.022 IU/mL (95% CI, 0.014-0.035 IU/Ml) before vaccination to 0.201 IU/mL (95% CI, 0.091-0.42 IU/mL) 28 days post-vaccination. Prior to vaccination, 47.8% of subjects in the ETIG group and 55.2% in the HT-ETIG group had human antitetanus antibody levels of at least 0.01 IU/mL (Table 4) . One month after vaccination, seroprotection at the 0.01 IU/mL level was seen in 83.6% of subjects in the ETIG group and 72.7% in the HT-ETIG group. Considering definite seroprotective threshold of 0.1 IU/mL prior to vaccination, 20.9% of subjects in the ETIG group and 17.9% in the HT-ETIG group were seroprotected. One month after vaccination, definite seroprotection was observed in 60.0% and 58.2% of subjects in the ETIG and HT-ETIG groups, respectively. Considering Day 28 post-vaccination, despite some differences between the groups in GMT levels and seroprotection rates, none achieved statistical significance. In the subjects with undetectable tetanus-antibody titre (Ͻ 0.01 IU/mL) prior to vaccination, the antibody response was lower than that of the whole population in terms of GMT 28 days postvaccination.
A strong response to diphtheria vaccine was observed in both groups (Table 4) . Anti-diphtheria antibodies increased from 0.082 IU/mL (95% CI, 0.057-0.118 IU/mL) before vaccination to 2.95 IU/ml (95% CI, 2.10-4.15 IU/mL) 28 days post-vaccination in the ETIG group, and from 0.069 IU/mL (95% CI, 0.047-0.102 IU/mL) to 2.79 IU/mL (95% CI, 2.0-3.90 IU/mL) in the HT-ETIG group. At the 0.1 IU/ mL protective level, 44% of subjects in the ETIG group and 41% in the HT-ETIG group were seroprotected before vaccination. All subjects except one in the ETIG group reached this level 28 days later.
Efficacy. No clinical cases of tetanus occurred during the follow-up (28 days).
Safety. Safety analysis was performed on 132 patients Tetanus antibodies All subjects n ϭ 67 n ϭ 55 n ϭ 67 n ϭ 55 mean 95% CI range (min-max) (safety data on two patients in the HT-ETIG group who left the study after the first visit were not recorded). No serious adverse reactions were reported. In the HT-ETIG group, four days after injection one patient presented with a facial edema which disappeared 4 days later. The relationship of this event to treatment could not be determined. Local reaction rates were similar with 29.9% in ETIG group versus 30.8% in HT-ETIG group (Table 5) . Pain was the most frequently reported local reaction. All reactions were mild or moderate in intensity. The duration of adverse reactions were similar in the two groups.
To neither underestimate nor bias the systemic safety analysis, all systemic events with relation to the vaccine considered by investigators to be ''probable'' or ''unknown'' were taken into account in the analysis and considered to be related to immunization. Systemic reactions are summarized in Table 6 . There was no difference in the incidence of systemic reactions between the two groups. Headache was the most frequently reported systemic reaction. Most reactions were mild or moderate, except three reactions of severe intensity in the HT-ETIG group (one episode each of fever, insomnia, and headache which disappeared rapidly with symptomatic treatment). One patient in the HT-ETIG group presented with an episode of a serum sickness-like reaction (fever, arthralgia) six days after injection. The episode subsided in five days. 
DISCUSSION
The use of equine anti-tetanus immunoglobulins is of major interest in the post-exposure treatment of tetanus in developing countries. 10 This study evaluated the safety and immunologic protective effect of a new equine tetanus immunoglobulin in which a pasteurization step has been added. It was compared to the currently available equine tetanus immunoglobulin. The study was performed in Africa under field conditions in subjects who presented with a tetanusprone wound and who had not been immunized against tetanus for at least 10 years.
There were no serious adverse events related to the vaccine; in particular, no case of immediate anaphylactic shock. Similar rates of local reactions consisting mostly of mild or moderate pain occurred in both groups. Likewise the rates of systemic reactions and the type of reactions were similar in the two groups. Most of these reactions were mild or moderate. Anaphylactic shock after administration of heterologous purified F(abЈ) 2 fragments has been rarely reported, e.g., an incidence of 1:40,000, 12 and delayed reactions, such as serum sickness-like reactions, have been reported in approximately 1% of treated subjects. 12, 14 In our study, one case of serum sickness-like reaction with fever and arthralgia was reported that was considered to be possibly related to HT-ETIG. Hence, in this series of patients, the benefit in terms of viral safety afforded by the pasteurization step does not appear to be associated with significant worsening of the HT-ETIG safety profile.
The seroprotective effect of anti-tetanus F(abЈ) 2 fragments was determined using an ELISA that specifically detects such fragments. The titers in the HT-ETIG group and in the ETIG group showed a similar pattern of change after immunization. However the levels were significantly higher in the HT-ETIG group. The difference between the two may be due to the antibody (ELISA) titration method or, to a higher bioavailability of the new pasteurized form, as has previously been shown for heat-treated rabies immunoglobulin. 15 On the first day after immunization, nearly all subjects reached the minimum seroprotection level of equine antitetanus F(ab') 2 (0.01 IU/mL). The antibody levels induced by HT-ETIG and the time taken to reach a protective threshold is of particular importance after a tetanus wound, especially in light of low baseline antibody titers (only 50% of the subjects were above the minimum protective threshold of 0.01 IU/mL); and because the incubation period of tetanus can be as short as 3 or 4 days. 16 Incubation periods of less than 7 days correlate with severe disease and frequent complications. In addition, in our population the mean time between sustaining the wound and treatment initiation was 1.5 Ϯ 2.9 days. Thus, prompt administration of tetanus immunoglobulin to neutralize the toxin rapidly in patients with tetanus-prone wounds is crucial.
The persistence of anti-tetanus F(abЈ) 2 fragments is also important when considering the time and duration of tetanustoxin appearance, and the time needed to respond to vaccine. Using a radioimmunometric assay, we determined in a randomized subgroup of 35 subjects the half-life of total F(abЈ) 2 . The half-life in the HT-ETIG group (mean Ϯ SD ϭ 50.3 Ϯ 20 hr) was not different from the ETIG group (53.8 Ϯ 17.1 hr). The observed half-life agrees with results previously reported when equine F(abЈ) 2 fragments were administered by intramuscular route. 17, 18 A similar percentage of subjects (84% and 82%) in the ETIG and HT-ETIG groups, maintained a minimum protective level of equine F(abЈ) 2 for up to 14 days after injection. One week after treatment, 85% of subjects in the ETIG group and 93% in the HT-ETIG group were protected at a level Ն 0.05 IU/mL. At the level 0.1 IU/mL, 80% of subjects in the HT-ETIG group versus 38% in the ETIG group presented protective antibody titers (Ն 0.1 IU/mL). Persistence of equine tetanus F(abЈ) 2 fragments covers the therapeutic window before the antibody response to vaccine appears ( Figure 3 ). This is of clinical importance in view of the absence of an early antitoxin response to tetanus booster in our study, similar to previous observations, when a delay in the response to the vaccine may occur, such as among the elderly or those not previously-immunized. 13, [19] [20] [21] The relatively moderate and similar tetanus antibody response to one dose of Td vaccine in the two groups contrasts sharply with the brisk anamnestic response observed after one dose of Td vaccine in European subjects, all of whom had been immunized by potent tetanus toxoid at least 10 years before. 13 According to the inclusion criteria, the enrolled subjects in the current study had not received tetanus vaccination for at least ten years, and probably most of them had incomplete primary immunization. Therefore it is likely that the moderate antibody response to the tetanus component observed reflects a primary response to vaccination due to incomplete or absent immunologic priming, rather than interference between vaccine and anti-tetanus serum. 22, 23 This point is clearly demonstrated by the fact that nearly half of subjects had undetectable antibody titer before vaccination and had a poor immune response (in terms of geo-FIGURE 3. Geometric mean titers (GMT) of anti-tetanus antibodies (the highest value between human antibodies and equine tetanus F(abЈ) 2 titer) (mean and 95% confidence intervals [CI], log-linear scale) after administration of equine tetanus immunoglobulin (ETIG) ϩ tetanus-diphtheria (Td) vaccine or heat-treated equine tetanus immunoglobulin (HT-ETIG) ϩ Td vaccine. metric mean titer) after immunization. The antibody response to diphtheria vaccine was comparatively higher, suggesting that these subjects had had previous contact with diphtheria (natural immunity), probably by cutaneous contamination. 3 Nevertheless, we stress the continued importance of diphtheria vaccination in view of the low seroprevalence of diphtheria antibodies reported in adults in developed countries (Miller E and Rush M, unpublished data).
An increase in the level of anti-tetanus fragments F(abЈ) 2 and pharmacokinetic parameters after HT-ETIG administration confirm that pasteurization does not alter the immunologic properties of anti-tetanus serum as has recently been demonstrated with anti-rabies F(abЈ) 2 fragments, human antirabies immunoglobulin, and human anti-tetanus immunoglobulin. 13, 15, 18 In addition, no difference in terms of immunogenicity and safety profile were found among the three different lots of HT-ETIG (data not shown). Taking into account the high risk of tetanus in this population and the fact that nearly all cases of tetanus occur within one month after contamination, it is noteworthy that no clinical case of tetanus occurred during the study follow-up (28 days). 5, 7 Thus our data support current recommendations for the use of equine immunoglobulin for tetanus-prone wounds.
In conclusion, the pasteurized, purified anti-tetanus fragments F(abЈ) 2 have a good safety profile and induce significantly higher seroprotective levels of tetanus antibodies than the currently available product beginning one day post-administration. HT-ETIG can be safely used in the effective management of tetanus-prone wounds in association with the Td vaccine, representing a readily available, alternative to the human immunoglobulin.
